Latest News and Press Releases

Oslo, Norway, October 25, 2016 Photocure ASA announced that new data on Blue Light Cystoscopy with Cysview®/Hexvix® were presented at the Société Internationale d'Urologie (SIU) Annual meeting,...

Oslo, Norway, September 28th, 2016:  Photocure ASA announced today that a study published on-line in the peer reviewed Journal of Urology, shows that there is no significant statistical difference...

Reference is made to the announcement on 6 September 2016 in respect of a capital increase of 35 000 new shares following exercise of employee share options in the company. The share capital...

Oslo, Norway, September 12th, 2016: Photocure ASA announced today that data from the OPTIC III study:  Optimized photodynamic diagnosis for transurethral resection of the bladder tumor (TURBT) in...

Update on management shareholdings and exercise of employee share options in Photocure ASA ("the Company"). Oslo, Norway, 6 September 2016  1.  Participants in the Photocure's share option...

Oslo, Norway, August 29, 2016 -- Photocure ASA hosted on August 25 an educational event in New York aimed at institutional investors and analysts, which focused on the treatment of bladder cancer....

Oslo, Norway, August 24, 2016: Photocure ASA (OSE: PHO), announces that its partner and exclusive distributor, Juno Pharmaceuticals Pty Ltd, have received marketing authorization approval (MAA) for...

Oslo, Norway, 23 August 2016: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, reported a sales revenue growth of 18 % to...

Photocure will present its second quarter report on Tuesday 23 August 2016 at Hotel Continental, Oslo, Norway. Additionally, Dr. Daneshmand will provide an update on Hexvix/Cysview following the...

New Cysview kit has an improved design providing healthcare professionals with an improved, simplified, and easy-to-use product. Oslo, Norway, August 11, 2016: Photocure ASA (OSE: PHO), announces...